Development of a Bioluminescent Cell-Based Assay to ... - Promega
Development of a Bioluminescent Cell-Based Assay to ... - Promega
Development of a Bioluminescent Cell-Based Assay to ... - Promega
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Introduction <strong>to</strong> the reporter bioassay for Fc effec<strong>to</strong>r<br />
function in MOA pathway<br />
NFAT-RE luciferase bioassay<br />
Low Variability<br />
Developed using:<br />
• CD20 and Her2 Ab drugs<br />
• CD20+ and Her2+ target cells<br />
• Frozen, thaw-and-use, or<br />
continuously cultured cells<br />
• Extensive ‘alpha’ evaluations:<br />
- tested in multiple global biopharma &<br />
biotechs<br />
- tested in multiple systems<br />
Confidential and Proprietary. Not for Further Disclosure.<br />
1. Effec<strong>to</strong>r cells are engineered <strong>to</strong><br />
express FcgRIIIa (V158) and NFAT-<br />
RE-luc2 luciferase<br />
2. ‘<strong>Cell</strong>s as reagents’<br />
(thaw-and-use)<br />
3. Homogeneous assay format –<br />
simple ‘add-mix-read’<br />
bioluminescent assay.<br />
4. Optimized and robust assay<br />
reagents and pro<strong>to</strong>col<br />
5. Performance characteristics that<br />
meet needs <strong>of</strong> stability testing, lot<br />
release and Ab characterization<br />
4
Change language